Automated Insulin Delivery Effectively Titrates Basal Insulin in Type 2 Diabetes

Automated insulin delivery systems, already a mainstay for many with type 1 diabetes, are showing promise as a tool to streamline basal insulin adjustments for individuals managing type 2 diabetes. Recent findings presented at the International Conference on Advanced Technologies & Treatments for Diabetes suggest these systems can achieve glycemic control comparable to traditional, clinician-guided titration methods, potentially addressing a significant bottleneck in diabetes care.

Faster Titration, Reduced Burden?

Currently, achieving optimal basal insulin dosing – the long-acting insulin that provides a steady background level – can be a lengthy process. American Diabetes Association standards of care acknowledge that titration often takes up to 16 weeks, hampered by infrequent follow-up appointments, patient reluctance, and the sheer workload faced by healthcare professionals. Researchers are exploring whether automated insulin delivery (AID) systems can accelerate this process.

Heman Shakeri, PhD, assistant professor at the University of Virginia School of Data Science, presented data from a pilot study examining the use of the Control-IQ system (Tandem Diabetes Care) for a 10-day titration period in adults with type 2 diabetes. The study compared outcomes to a control group receiving standard care with continuous glucose monitoring (CGM) and physician-guided adjustments. The results indicated that both groups experienced improvements in time in range – the percentage of time glucose levels remain within a target range of 70-180 mg/dL – but the AID system offered a potentially faster route to optimization.

Study Details and Glycemic Outcomes

The randomized controlled trial involved 16 adults with type 2 diabetes already on basal insulin and with an HbA1c of 7.5% or higher. Participants initially wore a masked CGM for 10 days to establish a baseline. Those assigned to the intervention group then used the Control-IQ system for another 10 days, with the system automatically adjusting basal insulin doses. The control group continued to wear a CGM but received guidance from a physician regarding dosage changes. A final 10-day masked CGM period followed to assess outcomes.

The intervention group saw a notable improvement in time in range, increasing from 55% at baseline to 67.3% after using the AID system. Time spent above range (180-250 mg/dL) decreased from 24.8% to 22.9%, and severe hyperglycemia (above 250 mg/dL) dropped significantly from 20.1% to 9.4%. The control group also showed improvements – time in range rose from 43.5% to 58.5%, and time above range decreased to 29.6% with severe hyperglycemia falling to 11.6% – but the gains were achieved through traditional methods.

Importantly, both groups experienced minimal time in hypoglycemia throughout the study, suggesting that the AID system did not compromise glucose safety.

What the Findings Mean for Patients and Providers

Dr. Shakeri emphasized that the AID system demonstrated comparable efficacy to standard clinician care in achieving basal insulin titration. “Automation is almost comparable to the daily expert care, meaning that for those clinics that doesn’t have the bandwidth, this can be a good alternative,” he stated. Here’s particularly relevant given the challenges many healthcare systems face in providing timely and comprehensive diabetes management.

The potential benefits extend beyond simply speeding up the titration process. AID systems can reduce the burden on both patients and providers, potentially leading to improved adherence and better overall glycemic control. Automated insulin delivery has already demonstrated success in type 1 diabetes, and these findings suggest a similar role may emerge in type 2 diabetes management.

Limitations and Future Directions

It’s crucial to acknowledge the limitations of this study. The small sample size (n=16) limits the statistical power and generalizability of the findings. Further research with larger, more diverse populations is needed to confirm these results. Dr. Shakeri noted that the study was not powered to demonstrate statistical significance, but the observed trends are encouraging.

The study also focused on a relatively short titration period (10 days). Longer-term studies are needed to assess the durability of the benefits and to determine the optimal duration of AID-assisted titration. Ongoing research is also exploring the potential of integrating AID systems with other diabetes technologies, such as advanced CGM sensors and insulin pumps.

The Evolving Landscape of Diabetes Technology

The development of AID systems represents a significant advancement in diabetes technology. These systems use algorithms to automatically adjust insulin delivery based on real-time glucose data, aiming to maintain glucose levels within a target range. While initially designed for type 1 diabetes, the application of AID systems to type 2 diabetes is gaining momentum, driven by the need for more efficient and effective management strategies.

The findings from Dr. Shakeri’s study add to a growing body of evidence supporting the potential of AID systems to transform diabetes care. As technology continues to evolve and more research emerges, these systems may become an increasingly valuable tool for both patients and healthcare providers in the fight against type 2 diabetes.

What comes next: Researchers plan to conduct larger, multi-center trials to validate these findings and to refine AID algorithms for optimal performance in diverse populations with type 2 diabetes. The FDA will likely continue to review data on AID systems as they become more widely adopted, potentially leading to expanded indications and improved access for patients.